Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...

NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection ...

A once-daily polypill containing 3 guideline-directed therapies for heart failure with reduced ejection fraction (HFrEF) led ...

Providing healthy, medically tailored meals or boxes of fresh produce along with nutrition counseling with a dietitian led to ...

There’s a supplement that’s been a game-changer for many of us with sleep concerns. It’s called melatonin, and it’s a hormone ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a “polypill” combination of three medications typically prescribed for heart failure, once daily for six months, ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Providing healthy, medically tailored meals or boxes of fresh produce along with nutrition counseling with a dietitian led to ...

A study found adults using melatonin for over a year had higher risks of heart failure and hospitalization, though some ...

Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines. An unusual study presented at the European Society of Cardiology (ESC) congress in ...